Findings from M.D. Anderson Cancer Center Provides New Data about Cellular and Molecular Medicine (Clinical applications of palifermin: amelioration of oral mucositis and other potential indications)
By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Biotechnology have been published. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "Mucositis is one of the most significant toxicities in cancer patients undergoing cytotoxic treatment. It can have a negative impact on both quality of life and health economics."
Our news journalists obtained a quote from the research from M.D. Anderson Cancer Center, "Severe oral mucositis can contribute to hospitalization, need for narcotic analgesics, total parentral nutrition, suboptimal delivery of anti-neoplastic treatment, and morbidity and mortality. Palifermin, a recombinant derivative of human keratinocyte growth factor, is the first active agent approved by the FDA for the prevention of severe oral mucositis in patients undergoing haematopoietic stem cell transplantation (HSCT). Several studies have also shown significant reduction in the incidence, severity and/or duration of oral mucositis in other high-risk settings such as concurrent chemoradiotherapy (CT/RT) for patients with head and neck cancer, and use of mucotoxic chemotherapeutic agents such as doxorubicin in sarcoma and fluorouracil for the treatment of colorectal cancer. The reduction in mucositis has translated into amelioration of symptoms and improvement in daily functioning as measured by patient-reported outcome in multiple studies. The clinical response to palifermin appears to be related in part to epithelial proliferation and mucosal thickening. Palifermin also has other potential clinical applications including the acceleration of immune reconstitution and inhibition of graft-versus-host disease in patients undergoing HSCT, and mitigation of dysphagia in lung cancer patients treated with concurrent CT/RT. Palifermin is generally well tolerated with mild-to-moderate skin and oral adverse events."
According to the news editors, the research concluded: "Future studies may expand the use of palifermin into other areas that would benefit from its cytoprotective and regenerative effects."
For more information on this research see: Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. Journal of Cellular and Molecular Medicine, 2013;17(11):1371-84. Journal of Cellular and Molecular Medicine can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Cellular and Molecular Medicine - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934)
The news correspondents report that additional information may be obtained from S. Vadhan-Raj, Dept. of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Additional authors for this research include J.D. Goldberg, M.A. Perales, D.P. Berger and M.R van den Brink (see also Biotechnology).
The publisher's contact information for the Journal of Cellular and Molecular Medicine is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.
Keywords for this news article include: Biotechnology, Texas, Cancer, Houston, Oncology, United States, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC